Original Research
Accepted on 21 Nov 2024
Proteomic study of the inhibitory effect of Tannic acid on MRSA biofilm
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1413669
Type at least 3 characters
318 articles
Articles
Original Research
Accepted on 20 Nov 2024
Signal Detection and Analysis of Adverse Events Associated with Genvoya® based the FAERS Database
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1439781
Review
Published on 20 Nov 2024
Natural compounds in the fight against Staphylococcus aureus biofilms: a review of antibiofilm strategies
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1491363
- 173 views
Original Research
Published on 18 Nov 2024
Comparative bactericidal activity of four macrolides alone and combined with rifampicin or doxycycline against Rhodococcus equi at concentrations achievable in foals
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1458496
- 291 views
Original Research
Published on 15 Nov 2024
Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1437400
- 256 views
Original Research
Published on 13 Nov 2024
Low-dose trimethoprim-sulfamethoxazole treatment for Pneumocystis pneumonia: a systematic review and meta-analysis
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1422490
- 148 views
Original Research
Accepted on 12 Nov 2024
Impact on parasitemia, survival time and pro-inflammatory immune response in mice infected with Plasmodium berghei treated with Eleutherine plicata
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1484934
Review
Accepted on 12 Nov 2024
Voriconazole: A review of adjustment programs guided by therapeutic drug monitoring
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1439586
Correction
Published on 06 Nov 2024
Corrigendum: ArboItaly: leveraging open data for enhanced arbovirus surveillance in Italy
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1517547
- 181 views
Review
Published on 06 Nov 2024
COVID-19 vaccines: current and future challenges
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1434181
- 732 views
Clinical Trial
Published on 06 Nov 2024
Investigation on improving immunologic reconstitution insufficiency using DiwuYanggan capsules in AIDS patients
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1485719
- 317 views
Original Research
Published on 05 Nov 2024
Thanatin and vinyl sulfide analogues as narrow spectrum antimicrobial peptides that synergise with polymyxin B
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1487338
- 336 views
Original Research
Published on 05 Nov 2024
Development of prediction models for carbapenem-resistant Klebsiella pneumoniae acquisition and prognosis in adult patients
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1439116
- 195 views
Systematic Review
Published on 31 Oct 2024
The efficacy and safety of addition of pegylated interferon to long-term nucleos(t)ide analogue therapy on functional cure of chronic hepatitis B patient: a systematic review and meta-analysis
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1474342
- 652 views
Brief Research Report
Published on 30 Oct 2024
First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1347306
- 289 views
Brief Research Report
Published on 28 Oct 2024
Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study
in Pharmacology of Infectious Diseases
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1341612
- 328 views